Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELBA: Exemestane and Lapatinib in Advanced Hormone-responsive Breast Cancer
NCT01005641Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Dec 2009
- Primary completion
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of lapatinib in breast cancer, sponsored by National Cancer Institute. Planned start Dec 2009; status: withdrawn.
02
Drugs
lapatinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01005641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01005641.